Pharmaceutical management in targeted radionuclide therapy study
Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.
This study is for adults who are getting targeted radionuclide therapy and have a pharmacist involved in managing their medicines. It looks at how the medication is handled to improve treatment safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You are receiving targeted radionuclide therapy (a type of cancer treatment that uses radioactive drugs)
- A pharmacist or healthcare professional has reviewed your medication as part of this therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study creates a database of information and blood samples from patients receiving a type of treatment called metabolic radiotherapy for certain cancers, like thyroid, neuroendocrine, or prostate cancer. It aims to improve understanding and care for future patients.
This trial tests a personalized form of radiation therapy that targets a protein called PSMA found on some cancer cells. It may help people whose cancer has spread or cannot be removed with surgery, and has not responded to other treatments.
This trial tests how much radiation a specialized whole-body PET/CT scan delivers in patients with differentiated thyroid cancer. It may help doctors better plan treatment for cancer that persists, returns, or has spread—especially when radioactive iodine (RAI) may or may not work.
This study looks at whether certain cancer “targeted therapy” medicines can make radioactive iodine (RAI) therapy work better for thyroid cancer that has spread to the lungs. It also involves taking special whole-body scans to measure how much radioactive iodine gets taken up by the cancer.
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.